In clinical trials, more than half of all patients treated with deucravacitinib achieved at least 20% improvement in American College of Rheumatology response criteria.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-approves-deucravacitinib-first-tyk2-inhibitor-psa-2026a100076x?src=rss
Author :
Publish date : 2026-03-09 17:35:00
Copyright for syndicated content belongs to the linked Source.
